Thienopyridazinones and their use in modulation of autoimmune disease

A compound of formula (1):

• wherein:
• R1 and R2 each independently represent C1-6alkyl, C3-6alkenyl, C3-5cycloalkylC1-3alkyl or C3-6cycloalkyl, each of which may be optionally substituted by 1 to 3 halogen atoms;
• Q is CR4R5 where R4 is hydrogen, fluorine or C1-6 alkyl and R5 is hydrogen, fluorine or hydroxy;
• Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from C1-4alkyl (optionally substituted by 1, 2 or 3 hydroxy groups), C1-4alkoxy, halogen, haloalkyl, dihaloalkyl, or trihaloalkyl, (wherein alkyl groups suitably contain from 1 to 4 carbon atoms) C1-4alkoxyC1-4alkyl, C1-4alkylthio, C1-4alkoxycarbonyl, C2-4alkanoyl, oxo, thioxo, nitro, cyano, —N(R6)R7 and
• —(CH2)pN(R8)R9, hydroxy, C1-4alkylsulphonyl, C1-4alkylsulphinyl, carbamoyl,
• C1-4alkylcarbamoyl, di-(C1-4alkyl)carbamoyl, carboxy, SO2N(R8)R9;
• Ar2 is a 5 or 6 membered aromatic ring containing up to 4 hetero atoms independently selected from nitrogen, sulphur or oxygen, and which may be optionally substituted by one or more groups independently selected from C1-4alkyl (optionally substituted by 1, 2 or 3 hydroxy groups), C1-4alkoxy, halogen, haloalkyl, dihaloalkyl, or trihaloalkyl, (wherein alkyl groups suitably contain from 1 to 4 carbon atoms) C1-4alkoxyC1-4alkyl, C1-4alkylthio, C1-4alkoxycarbonyl, C2-4alkanoyl, oxo, thioxo, nitro, cyano, —N(R6)R7 and —(CH2)pN(R8)R9, hydroxy, C1-4alkylsulphonyl, C1-4alkylsulphinyl, carbamoyl, C1-4alkylcarbamoyl, di-(C1-4alkyl)carbamoyl, carboxy, SO2N(R8)R9;
• p is 1 to 4;
• R6 and R7 each independently represent a hydrogen atom, C1-4alkanoyl or C1-4alkyl group, or together with the nitrogen atom to which they are attached form a 5- to 7-membered saturated heterocyclic ring optionally containing a further O, S, NH or Nalkyl group;
• R8 and R9 each independently represent a hydrogen atom, C1-4alkanoyl or C1-4alkyl group, or together with the nitrogen atom to which they are attached form a 5- to 7-membered saturated heterocyclic ring optionally containing a further O, S, NH or Nalkyl group;
• or a pharmaceutically acceptable salt or solvates thereof, provided that the compound is other than 5-[(4S)-4-Hydroxyisoxazolidin-2-ylcarbonyl]-1-(isobutyl)-3-methyl-6-[5-methyl-3-phenyl-1H-pyrazol-4-ylmethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,
• 6-[3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl]-5-[(4S)-4-hydroxyisoxazolidin-2-ylcarbonyl]-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or
• 6-[3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl]-5-[(4S)-4-hydroxyisoxazolidin-2-ylcarbonyl]-3-methyl-1-propylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt or solvate thereof.